Back to top
more

Allogene Therapeutics (ALLO)

(Delayed Data from NSDQ)

$1.04 USD

1.04
3,658,894

-0.01 (-0.95%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $1.04 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (147 out of 244)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Allogene Therapeutics (ALLO) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Allogene Therapeutics (ALLO) delivered earnings and revenue surprises of -7.94% and 35%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Amarin's (AMRN) Q1 Earnings Top, Vascepa Sales Fall

by Zacks Equity Research

Amarin's (AMRN) first-quarter 2023 earnings and revenues beat estimates. Vascepa sales decline.

Zacks Equity Research

Repligen (RGEN) Beats on Q1 Earnings, Lowers 2023 Guidance

by Zacks Equity Research

Repligen's (RGEN) first-quarter earnings and revenues beat estimates.

Zacks Equity Research

Sarepta (SRPT) Q1 Earnings Beat Estimates, Revenues Up Y/Y

by Zacks Equity Research

Sarepta (SRPT) delivers narrower-than-expected loss per share in first-quarter 2023. Total revenues beat estimates on the back of strong product sales growth during the quarter.

Zacks Equity Research

CRISPR (CRSP) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

On CRISPR's (CRSP) first-quarter earnings call, investors will likely focus on its pipeline, especially its lead candidate exa-cel, due to the absence of marketed drugs.

Zacks Equity Research

Should You Buy Allogene Therapeutics (ALLO) Ahead of Earnings?

by Zacks Equity Research

Allogene Therapeutics (ALLO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Equity Research

Novo Nordisk (NVO) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Novo Nordisk's (NVO) Diabetes and Obesity Care products are expected to have increased sales in the first quarter of 2023, amid severe competition and pricing pressure in the United States.

Zacks Equity Research

Perrigo (PRGO) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Perrigo's (PRGO) new products and products added through acquisitions are expected to have aided the company's top line in the soon-to-be-reported quarter.

Zacks Equity Research

Zoetis (ZTS) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Higher sales of Zoetis' (ZTS) key drugs like Apoquel, Cytopoint, Simparica Trio, Librela and Solensia are likely to have driven first-quarter sales.

Zacks Equity Research

AbCellera Biologics Inc. (ABCL) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

AbCellera Biologics Inc. (ABCL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Will Jakafi Sales Drive a Beat For Incyte (INCY) Q1 Earnings?

by Zacks Equity Research

Incyte's (INCY) first-quarter 2023 earnings are likely to have gained from higher Jakafi sales and incremental sales from newly approved drugs.

Zacks Equity Research

Allogene Therapeutics (ALLO) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Allogene Therapeutics (ALLO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Ocuphire (OCUP) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Occuphire (OCUP) is expected to provide updates on its proprietary ophthalmic platform for treating refractive and retinal eye disorders, on its first-quarter earnings call.

Zacks Equity Research

Wall Street Analysts Believe Allogene Therapeutics (ALLO) Could Rally 278.19%: Here's is How to Trade

by Zacks Equity Research

The mean of analysts' price targets for Allogene Therapeutics (ALLO) points to a 278.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Equity Research

Allogene Therapeutics (ALLO) Surges 8.4%: Is This an Indication of Further Gains?

by Zacks Equity Research

Allogene Therapeutics (ALLO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

Dermata (DRMA) Gains on Positive FDA Response for Acne Candidate

by Zacks Equity Research

Dermata (DRMA) gains on positive FDA response for the further development of DMT310 for treating severe to moderate acne.

Zacks Equity Research

Axsome (AXSM) Focuses on Auvelity Launch to Fuel Its Growth

by Zacks Equity Research

Axsome's (AXSM) earnings benefit from the launch of Auvelity (AXS-05), meant for treating major depressive disorders.

Zacks Equity Research

VYNE Gains on Preclinical Data for IPF Candidate

by Zacks Equity Research

VYNE gains on positive preclinical data evaluating VYN201 for treating idiopathic pulmonary fibrosis.

Zacks Equity Research

Here's Why You Should Add Allogene (ALLO) Stock to Your Portfolio

by Zacks Equity Research

Allogene Therapeutics (ALLO), a top-ranked stock, is currently focused on developing allogenic CAR T therapies for treating cancer.

Zacks Equity Research

Madrigal (MDGL) Gains on NASH Treatment's Breakthrough Therapy Tag

by Zacks Equity Research

Madrigal Pharmaceuticals (MDGL) gains on receiving Breakthrough Therapy designation from the FDA for resmetirom.

Zacks Equity Research

Gamida Cell (GMDA) Surges on FDA Approval for Omisirge

by Zacks Equity Research

Gamida Cell's (GMDA) shares surge as it receives FDA approval for Omisirge, an allogeneic cell therapy for blood cancer patients.

Zacks Equity Research

Humanigen (HGEN) Surges on Lenzilumab Study Data for Leukemia

by Zacks Equity Research

Humanigen's (HGEN) shares surge after presenting promising early results of its Precision Approach to Chronic Myelomonocytic Leukemia study of lenzilumab in chronic myelomonocytic leukemia.

Zacks Equity Research

Alvotech (ALVO) Declines on CRL for Humira's Biosimilar Candidate

by Zacks Equity Research

Alvotech's shares decline as it receives a complete response letter for biosimilar candidate, AVT02, treating autoimmune disorders.

Zacks Equity Research

Regulus (RGLS) Surges on Enrollment Completion for RGLS8429

by Zacks Equity Research

Regulus (RGLS) surges as it completes enrollment in the first cohort to evaluate RGLS8429 for kidney disease.

Zacks Equity Research

Panbela (PBLA) Enrolls First Patient for Type 1 Diabetes Drug

by Zacks Equity Research

Panbela (PBLA) surges as it enrolls the first patient in the mid-stage clinical study to evaluate CPP-1X-T (Eflornithine tablets) for treating recent-onset type 1 diabetes.